Scholarlink

<p>Hepatic fibrosis, a critical progression in liver disease, has been widely studied. While the activation of stellate cells and the accumulation of extracellular matrix components are recognized as key mechanisms, additional research is necessary to uncover further complexities. Recent investigations underscore the pivotal role of post-translational modifications (PTMs) in hepatic fibrosis. This study explores nine PTMs—methylation, acetylation, SUMOylation, Neddylation, phosphorylation, crotonylation, glycosylation, lactylation, and ubiquitination—each implicated in the pathogenesis of hepatic fibrosis. Furthermore, six classes of drugs—ACC inhibitors, ASK1 inhibitors, Akt activators, FXR agonists, PTP1B inhibitors, and HDAC inhibitors—are reviewed for their therapeutic potential in targeting PTMs to treat hepatic fibrosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanistic insights into post-translational modifications in hepatic fibrosis: pathogenic roles and therapeutic potentials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月1日

查看全文
  • Xiwen Bai,
  • Zhihan Liu,
  • Xianbin Li,
  • Ranran Sun,
  • Zujiang Yu

摘要

Hepatic fibrosis, a critical progression in liver disease, has been widely studied. While the activation of stellate cells and the accumulation of extracellular matrix components are recognized as key mechanisms, additional research is necessary to uncover further complexities. Recent investigations underscore the pivotal role of post-translational modifications (PTMs) in hepatic fibrosis. This study explores nine PTMs—methylation, acetylation, SUMOylation, Neddylation, phosphorylation, crotonylation, glycosylation, lactylation, and ubiquitination—each implicated in the pathogenesis of hepatic fibrosis. Furthermore, six classes of drugs—ACC inhibitors, ASK1 inhibitors, Akt activators, FXR agonists, PTP1B inhibitors, and HDAC inhibitors—are reviewed for their therapeutic potential in targeting PTMs to treat hepatic fibrosis.